Suturable bioprinted vascularized muscle constructs for treatment of skeletal muscle loss

用于治疗骨骼肌损失的可缝合生物打印血管化肌肉结构

• 批准号: 10353393
• 负责人: Su Ryon Shin
• 金额: $ 53.65万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-01 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10353393
• 关键词: 3-Dimensional; Address; Affect; Alginates; Allografting; Architecture; Area; Autologous Transplantation; Biocompatible Materials; Biomimetics; Blood Vessels; Cell Survival; Cells; Characteristics; Cicatrix; Clinical; Collagen; Complex; Elderly; Electrophysiology (science); Electrospinning; Endothelial Cells; Endothelium; Engineering; Extracellular Matrix; Fibrosis; Functional Regeneration; Gelatin; Growth; Growth Factor; Hematopoietic; Hydrogels; Image; Immune response; Impairment; Implant; Infection; Injury; Insulin-Like Growth Factor I; Kinetics; Lasers; Methods; Modeling; Morbidity - disease rate; Muscle; Muscle Fibers; Muscle function; Muscular Atrophy; Musculoskeletal Diseases; Myoblasts; Nerve Regeneration; Neuromuscular Junction; Nude Mice; Operative Surgical Procedures; Pain; Patients; Persons; Physiological; Population; Positioning Attribute; Printing; Production; Protocols documentation; Quality of life; Recovery; Regenerative Medicine; Regenerative capacity; Reproducibility; Scheme; Site; Skeletal Muscle; Soldier; Surgical sutures; System; Techniques; Testing; Therapeutic; Thick; Tissue Grafts; Tissue constructs; Tissues; Traumatic injury; Vascular Endothelial Cell; Vascular blood supply; Vascular regeneration; Vascularization; angiogenesis; base; bioink; biomaterial compatibility; bioprinting; cell assembly; clinically relevant; directed differentiation; disability; functional disability; functional restoration; healing; human pluripotent stem cell; implantation; improved; in vivo; induced pluripotent stem cell; injured; mechanical properties; migration; mouse model; muscle engineering; muscle form; muscle regeneration; nanofiber; nerve injury; neuromuscular; personalized medicine; physical property; poly(glycerol-sebacate); precursor cell; quadriceps muscle; regeneration function; repaired; restoration; satellite cell; scaffold; self assembly; skeletal muscle wasting; stem cell delivery; stem cell differentiation; subcutaneous; technology development; traumatic event; treadmill; vehicular accident; volumetric muscle loss

Project Summary Volumetric muscle loss (VML) usually occurs following traumatic injury and results in a composite loss of muscle mass. These injuries manifest in decreased strength and functional impairments. Clinically, these injuries often heal with fibrosis, as opposed to skeletal muscle regeneration. Current existing therapeutic options are also insufficient for VML treatment, and complications are often associated with surgical repair including nerve injury, excessive immune response, infection, scarring, and limitations of tissue graft supply. Indeed, natural healing and surgical procedures are inefficient in restoring the functionality of injured muscles, resulting in a poor quality of life. Therefore, developing clinically relevant three-dimensional (3D) tissue using patient-specific genetically identical cells has emerged as a potential solution to address the above issues. To achieve this aim, there are two existing main challenges. The first challenge is obtaining large amounts of patient-specific genetically identical cells. The use of human pluripotent stem cells (hiPSCs) differentiated to the muscle lineage represents a promising candidate to build upon personalized therapy. However, directing the differentiation of hiPSCs to the muscle fate along with reproducible differentiation schemes has proven to be challenging. The second challenge is developing a highly organized and vascularized 3D skeletal muscle tissue to maintain the viability of cells inside thick tissue constructs via engineered vessel networks. Furthermore, the fabricated tissues have to strongly integrate into injured site via surgical methods. To address these challenges, we plan to develop a suturable 3D vascularized muscle tissue from hiPSC-derived myogenic precursor cells (hiPSC-MPCs) embedded in biomaterials using bioprinting techniques. We will optimize the recently developed protocols allowing efficient production of functional myofibers from hiPSCs in hydrogels with tunable mechanical properties and degradable profiles, which mimic the extracellular matrix (ECM) of native skeletal muscle tissue. To create biomimetic vascularized muscle constructs, a multi-material embedded bioprinting technique will be used to precisely control the positions of the vascular network and aligned muscle fibers with biologically relevant architectures. With the conventional bioprinting system, it is difficult to precisely control the materials’ position in Z directions to create freestanding hydrogel architectures. Also, to achieve prolonged retention of implants into the injured site and to improve muscle regeneration, a muscle growth factor (IGF-1) laden suturable graft will be developed. hiPSC-MPCs-laden constructs will be printed on the suturable graft consisting of IGF-1-laden PGS/GelMA substrates using electrospinning.

项目摘要 容积性肌肉丧失(VML)通常发生在创伤后，导致综合的肌肉丧失 肌肉发达。这些损伤表现为力量下降和功能障碍。在临床上，这些 损伤通常以纤维化愈合，而不是骨骼肌再生。目前已有的治疗方法 VML治疗的选择也不充分，并发症往往与手术修复有关 包括神经损伤、免疫反应过度、感染、疤痕形成和组织移植物供应的限制。 事实上，自然愈合和外科手术在恢复受伤肌肉的功能方面效率低下， 导致生活质量不佳。因此，开发临床相关的三维(3D)组织使用 患者特有的基因相同的细胞已经成为解决上述问题的潜在解决方案。至 要实现这一目标，目前存在两个主要挑战。第一个挑战是获得大量的 患者特有的基因相同的细胞。人多能干细胞(HiPSCs)分化为 肌肉血统代表了个性化治疗的一个很有前途的候选者。然而，执导 HiPSCs对肌肉命运的分化以及可重复的分化方案已被证明 勇于挑战。第二个挑战是开发一种高度组织化和血管化的3D骨骼肌 组织通过工程化的血管网络维持厚组织结构内细胞的生存能力。 此外，制作的组织必须通过手术方法强烈整合到损伤部位。致信地址 面对这些挑战，我们计划从HiPSC来源的肌源性组织中开发一种可缝合的3D血管肌肉组织 利用生物打印技术将前体细胞(hiPSC-MPC)嵌入生物材料中。我们将优化 最近开发的方案允许在水凝胶中从HiPSCs高效地生产功能性肌纤维 具有可调的机械性能和可降解的轮廓，模拟细胞外基质(ECM) 天然骨骼肌组织。为了创造仿生的血管化肌肉结构，嵌入了多种材料 将使用生物打印技术来精确控制血管网络和排列的肌肉的位置 具有生物相关结构的纤维。使用传统的生物打印系统，很难精确地 控制材料在Z方向上的位置以创建独立的水凝胶结构。此外，要实现 延长植入物在损伤部位的滞留时间，促进肌肉再生，促进肌肉生长 将开发负载因子(IGF-1)的可缝合移植物。加载HiPSC-MPC的构造将打印在 可缝合移植物，由携带IGF-1的PGS/GelMA底物组成，使用静电纺丝。